ProCE Banner Activity

DREAM: Phase II Trial of First-line Combination Durvalumab Plus Chemotherapy in Advanced Mesothelioma

Slideset Download
Conference Coverage
In preliminary results, first-line combination chemoimmunotherapy with durvalumab achieved an ORR of 58% and 6-month PFS of 65% in advanced MPM.

Released: June 06, 2018

Expiration: June 05, 2019

No longer available for credit.

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Amgen, Inc.

Astellas Text

AstraZeneca

Celgene

Eisai

Genentech TEXT Only

Janssen

Merck Oncology

Seagen